Zydus Lifesciences Limited filed its Business Responsibility and Sustainability Report for the financial year ended March 31, 2026, disclosing key environmental and social performance metrics. The company reported a total energy consumption of 33,09,004 GJ, with renewable energy constituting 36% of the total energy mix. Total Scope 1 and Scope 2 emissions stood at 2,89,737 tCO2e, while the company achieved a waste disposal via co-processing rate of 28% for its India operations.

The report, submitted to BSE and NSE, outlines the company's sustainability commitments, including carbon neutrality in operations by FY 2035 and net water neutrality by FY 2028. Zydus stated that 56% of inputs were sourced sustainably from vendors and suppliers who have established ESG practices. The company has implemented a Zero Liquid Discharge mechanism across its manufacturing facilities, utilizing reverse osmosis and ultra-filtration systems to treat and repurpose wastewater.

Environmental Performance

Zydus disclosed its water withdrawal and consumption figures for FY 2025-26, reporting a total volume of water withdrawal of 25,57,721 kilolitres. The water intensity per rupee of turnover was recorded at 9.42 kl per revenue in million rupees. The company managed a total waste generation of 34,531.18 metric tonnes, with 24,001.48 metric tonnes recovered through recycling operations. Hazardous waste disposal included 1,710.07 metric tonnes via co-processing and 3,616.27 metric tonnes via pre-processing.

Social and Governance Metrics

The company reported a workforce of 24,618 permanent employees and 12,209 workers. Gender diversity on the Board of Directors was 22%, while the overall gender diversity for the company stood at 9% for FY 2026. The report indicated that 100% of permanent employees and workers were covered by health insurance. Zydus also disclosed that it received 1,480 customer complaints during the year, all of which were resolved, with zero pending at the close of the year.

The company’s Corporate Social Responsibility (CSR) initiatives benefited 4,65,523 persons directly. The report confirmed that the company is compliant with all applicable environmental laws and regulations, including the Water Act and Air Act. M/s SGS India Private Limited provided reasonable assurance for the BRSR core indicators.

Zydus Lifesciences Ltd has signed a Memorandum of Understanding (MoU) with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection (MCD) test in India. This partnership leverages the exclusive agreement between Zydus and Guardant Health, Inc., a precision oncology company, to introduce the methylation-based blood test across the country. The collaboration aims to address the low screening rates in India by making advanced diagnostic solutions more widely available through Apollo's extensive healthcare network.

Partnership Overview

The MoU establishes a framework for offering the Shield MCD test within Apollo Hospitals' territory. The test screens for 10 of the most common cancer types, including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian, and pancreas cancer. It is designed for individuals aged 45 or older who are at typical average risk for cancer.

Expanding Cancer Detection Capabilities

The Shield MCD test requires only a single blood draw to detect cancer-associated signals. It has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its potential to provide more effective screening than existing options. Cancer accounts for nearly nine per cent of total deaths related to non-communicable diseases in India, with over 1.41 million individuals diagnosed in 2022. By integrating this technology into Apollo Cancer Centres, the partners seek to enable earlier diagnosis and improve treatment outcomes.

Dr. Prathap C. Reddy, Chairman of Apollo Hospitals Group, emphasized that proactive healthcare is critical to reducing the impact of cancer. Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., highlighted the company's commitment to reimagining diagnostics in cancer care through precision screening technologies. Simranjit Singh, Chief Executive Officer of Guardant Health AMEA, noted that earlier detection has the potential to transform cancer outcomes in the region.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE010B01027/2c7aeda84f1c43bb.pdf